AB1093 LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Nash, Peter; B. McInnes, Iain; Shawi, M.; Nantel, F.; P. Kollmeier, Alexa; Rampakakis, Emmanouil; R. Soriano, Enrique; D. Gladman, Dafna; Deodhar, Atul

doi:10.1136/annrheumdis-2023-eular.366

Public

AB1093 LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Published • May 30, 2023

Authors:

Peter Nash

Iain B. McInnes

M. Shawi

Abstract

Background Treatment effects on PsA joint symptoms are assessed by ACR response rates, reflecting percentages of patients (pts) meeting a composite measure of improvement from baseline (BL) at specific timepoints. Alternatively, the ACR-numeric (ACR-N) is a continuous measure of improvement based on...

Subject

Medicine

Psoriatic arthritis

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!